In re application of : Mail Stop: Amendment

Mamoru OHASHI et al. : Attorney Docket No. 2000_0486A

Serial No. 09/529,715 : Group Art Unit 1616

Filed April 19, 2000 : Examiner Sharmila Gollamudi

FAST-DISSOLVING PHARMACEUTICAL

COMPOSITION

Confirmation No. 9675

TERMINAL DISCLAIMER UNDER 37 CFR 1.321

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The owner, Dainippon Pharmaceutical Co., Ltd., of 100% interest in the instant application, hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 USC 154 to 156 and 173, as shortened by any terminal disclaimer, of prior Patent No. 6,297,244, issued October 2, 2001. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 USC 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims

cancelled by a reexamination certificate; is reissued; or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

- \underline{X} The undersigned is empowered to act on behalf of the organization.
- \underline{X} The undersigned is an attorney of record.

November 3, 2005

By:

Warren M. Cheek, Jr., Reg. No. 33,367

Terminal disclaimer fee under 37 CFR 1.20(d) is included.

WMC/dlk Washington, D.C. 20006-1021 Telephone (202) 721-8200 Facsimile (202) 721-8250



HE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Confirmation No. 9675

Mamoru OHASHI et al.

Attorney Docket No. 2000 0486A

Serial No. 09/529,715

Group Art Unit 1616

Filed April 19, 2000

Examiner Sharmila Gollamudi

FAST-DISSOLVING PHARMACEUTICAL

Mail Stop: AMENDMENT

COMPOSITION

PATENT OFFICE FEE TRANSMITTAL FORM

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

THE COMMISSIONER IS AUTHORIZED TO CHARGE ANY DEFICIENCY IN THE FEE FOR THIS PAPER TO DEPOSIT ACCOUNT NO. 23-0975.

Sir:

Attached hereto is a check in the amount of \$130.00 to cover Patent Office fees relating to filing the following attached papers:

A duplicate copy of this paper is being submitted for use in the Accounting Division, Office of Finance.

The Commissioner is authorized to charge any deficiency or to credit any overpayment associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of deficiencies in fees for multiple dependent claims in new applications.

Respectfully submitted,

Mamoru OHASHI et al.

Warren M. Cheek, Jr.

Registration No. 33,367

Attorney for Applicants

WMC/dlk WENDEROTH, LIND & PONACK, L.L.P. 2033 K St., N.W., Suite 800 Washington, D.C. 20006-1021 Telephone (202) 721-8200 November 3, 2005

[Check No. 70989

2000 0486A